pe cy7 ebioscience rrid ab 469629 anti mouse cd19  (Thermo Fisher)

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: Injection of T3SS effectors not resulting in invasion is the main targeting mechanism of Shigella toward human lymphocytes

doi: 10.1073/pnas.1707098114

Figure Lengend Snippet: Characterization of lymphocytes isolated from human peripheral blood. Lymphocyte subsets were purified from peripheral blood of healthy donors. Following isolation, viability, purification efficiency, and activation status were assessed by flow cytometry using Live/Dead fluorescent dye and surface antibody staining. Purity (A), activation status (B), and viability (C) of B, CD4+ T, and CD8+ T cells were assessed with anti-human CD19, CD4, CD8a, CD44/CD86, CD69/CD25 fluorophore-conjugated antibodies and Live/Dead dye (black, nonactivated cells; red, activated cells; gray, unstained cells). Purity (D) and viability (E) of B-lymphocyte subsets was assessed with anti-human CD19/CD27, IgD/IgM/IgA/IgG fluorophore-conjugated antibodies and Live/Dead dye (gray: unstained cells; orange, blue: stained cells). Data are from one donor representative of three.

Article Snippet: Antibodies used for purity and activation status are listed in . table ft1 table-wrap mode="anchored" t5 Table S1. caption a7 Antibody Source Method CD3-APC Beckman, IOTest IM2467 FC CD3-Biotin eBioscience, 13-0038-82 FC CD3-FITC eBioscience, 11-0037-42 FC CD3 Dako, A0452 IHC CD4-PerCPCy5.5 eBioscience, 45-0048-73 FC CD8a-PE eBioscience, 12-0088-73 FC CD19-APC eBioscience, 17-0199-73 FC CD19-Biotin eBioscience, 13-0199-82 FC CD19-PacificBlue BioLegend, 302232 FC CD19-PE eBioscience, 12-0199-42 FC CD20cy Dako, M0755 IHC CD25-PE BD Pharmingen, 555432 FC CD27-PECy7 eBioscience, 25-0279-42 FC CD44-APC BD Pharmingen, 559942 FC CD45-PE-Vio770 Miltenyi, 130-098-148 FC CD45-APC BioLegend, BLE304011 FC CD69-APC BD Pharmingen, 555533 FC CD86-PE eBioscience, 12-0869-73 FC Epcam-PE Miltenyi, 130-098-115 FC IgA-FITC Miltenyi, 130-093-071 FC IgD-PerCPCy5 BD Pharmingen, 561315 FC IgG-PE BD Pharmingen, 555787 FC IgM-APCCy7 BioLegend, 314520 FC Streptavidin-Qdot705 Invitrogen, Q10163MP FC; 2 μL Mouse Ig-AF568 Thermo Fisher, {"type":"entrez-nucleotide","attrs":{"text":"A11021","term_id":"489240","term_text":"A11021"}} A11021 IHC; 1/500 Rabbit Ig-AF647 Thermo Fisher, {"type":"entrez-nucleotide","attrs":{"text":"A21245","term_id":"641367","term_text":"A21245"}} A21245 IHC; 1/500 Open in a separate window All anti-human antibodies were used for surface staining at 1/100 dilution, unless stated otherwise.

Techniques: Isolation, Purification, Activation Assay, Flow Cytometry, Staining

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: Injection of T3SS effectors not resulting in invasion is the main targeting mechanism of Shigella toward human lymphocytes

doi: 10.1073/pnas.1707098114

Figure Lengend Snippet: Human colonic lamina propria lymphocytes are preferentially targeted via injection-only upon in vitro infection with Shigella. (A) Confocal single slices of human colon specimen. B (CD20cy, red) and T lymphocytes (CD3, green); DAPI-stained nuclei (gray); phalloidin-associated actin (blue). Arrows denote B- and T-lymphocyte aggregates. (Scale bar: 50 μm.) (B–D) Analysis of CCF2-AM–loaded cells isolated from human colonic lamina propria and infected for 1 h at an MOI of 50 with Shigella WT-Rep-bla or WT-Ctrl-bla. (B) Flow cytometry analysis of targeted cells. Each dot represents one donor. Filled circles: WT-Rep-bla–infected cells; open circles: WT-Ctrl-bla–infected cells; filled squares: uninfected cells. ***P ≤ 0.001 (Student’s t test compared with WT-Ctrl-bla–infected cells). Data are from four independent donors. (C) Imaging cytometry quantification of invaded, injected-only, and PM-associated event proportions among targeted cells. Data from three independent donors are represented (analysis of ≈250 targeted cells per donor). (D) Representative images of imaging cytometry acquisition displaying lamina propria injected-only targeted cells with anti-human CD3 or CD19 surface staining.

Article Snippet: Antibodies used for purity and activation status are listed in . table ft1 table-wrap mode="anchored" t5 Table S1. caption a7 Antibody Source Method CD3-APC Beckman, IOTest IM2467 FC CD3-Biotin eBioscience, 13-0038-82 FC CD3-FITC eBioscience, 11-0037-42 FC CD3 Dako, A0452 IHC CD4-PerCPCy5.5 eBioscience, 45-0048-73 FC CD8a-PE eBioscience, 12-0088-73 FC CD19-APC eBioscience, 17-0199-73 FC CD19-Biotin eBioscience, 13-0199-82 FC CD19-PacificBlue BioLegend, 302232 FC CD19-PE eBioscience, 12-0199-42 FC CD20cy Dako, M0755 IHC CD25-PE BD Pharmingen, 555432 FC CD27-PECy7 eBioscience, 25-0279-42 FC CD44-APC BD Pharmingen, 559942 FC CD45-PE-Vio770 Miltenyi, 130-098-148 FC CD45-APC BioLegend, BLE304011 FC CD69-APC BD Pharmingen, 555533 FC CD86-PE eBioscience, 12-0869-73 FC Epcam-PE Miltenyi, 130-098-115 FC IgA-FITC Miltenyi, 130-093-071 FC IgD-PerCPCy5 BD Pharmingen, 561315 FC IgG-PE BD Pharmingen, 555787 FC IgM-APCCy7 BioLegend, 314520 FC Streptavidin-Qdot705 Invitrogen, Q10163MP FC; 2 μL Mouse Ig-AF568 Thermo Fisher, {"type":"entrez-nucleotide","attrs":{"text":"A11021","term_id":"489240","term_text":"A11021"}} A11021 IHC; 1/500 Rabbit Ig-AF647 Thermo Fisher, {"type":"entrez-nucleotide","attrs":{"text":"A21245","term_id":"641367","term_text":"A21245"}} A21245 IHC; 1/500 Open in a separate window All anti-human antibodies were used for surface staining at 1/100 dilution, unless stated otherwise.

Techniques: Injection, In Vitro, Infection, Staining, Isolation, Flow Cytometry, Imaging, Cytometry

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: Injection of T3SS effectors not resulting in invasion is the main targeting mechanism of Shigella toward human lymphocytes

doi: 10.1073/pnas.1707098114

Figure Lengend Snippet: Characterization of human colonic specimen and derived cells. Viability (A) and purity (B and C) of cells isolated from human colonic lamina propria were systematically assessed by flow cytometry before infection, using Live/Dead fluorescent dye and anti-human CD45, Epcam, CD3, and CD19 fluorophore-conjugated antibodies, respectively. Data from two independent donors are represented in orange and purple. Unstained cells are depicted in gray. (D) For imaging cytometry analysis, apoptotic, autofluorescent, and misshapen cells were excluded after selection of focused, single, live loaded cells (Fig. S5 A and B) and before quantification of targeting mechanisms (Fig. S5 C–E). Apoptotic cells (dying cells) were excluded from the analysis as those with high values in the Contrast (measuring the sharpness quality of the BF image) and the Side-Scatter intensity features of the BF image (Left). Cells with high autofluorescence in the DsRed image were removed by creating a threshold mask delineating the top 50% intensity pixels in this channel (Middle). Remaining misshapen cells were removed using the “find the best feature” procedure (41) that identified the Intensity and Modulation (measures the intensity range of an image, normalized between 0 and 1) features calculated on the BF channel (Right).

Article Snippet: Antibodies used for purity and activation status are listed in . table ft1 table-wrap mode="anchored" t5 Table S1. caption a7 Antibody Source Method CD3-APC Beckman, IOTest IM2467 FC CD3-Biotin eBioscience, 13-0038-82 FC CD3-FITC eBioscience, 11-0037-42 FC CD3 Dako, A0452 IHC CD4-PerCPCy5.5 eBioscience, 45-0048-73 FC CD8a-PE eBioscience, 12-0088-73 FC CD19-APC eBioscience, 17-0199-73 FC CD19-Biotin eBioscience, 13-0199-82 FC CD19-PacificBlue BioLegend, 302232 FC CD19-PE eBioscience, 12-0199-42 FC CD20cy Dako, M0755 IHC CD25-PE BD Pharmingen, 555432 FC CD27-PECy7 eBioscience, 25-0279-42 FC CD44-APC BD Pharmingen, 559942 FC CD45-PE-Vio770 Miltenyi, 130-098-148 FC CD45-APC BioLegend, BLE304011 FC CD69-APC BD Pharmingen, 555533 FC CD86-PE eBioscience, 12-0869-73 FC Epcam-PE Miltenyi, 130-098-115 FC IgA-FITC Miltenyi, 130-093-071 FC IgD-PerCPCy5 BD Pharmingen, 561315 FC IgG-PE BD Pharmingen, 555787 FC IgM-APCCy7 BioLegend, 314520 FC Streptavidin-Qdot705 Invitrogen, Q10163MP FC; 2 μL Mouse Ig-AF568 Thermo Fisher, {"type":"entrez-nucleotide","attrs":{"text":"A11021","term_id":"489240","term_text":"A11021"}} A11021 IHC; 1/500 Rabbit Ig-AF647 Thermo Fisher, {"type":"entrez-nucleotide","attrs":{"text":"A21245","term_id":"641367","term_text":"A21245"}} A21245 IHC; 1/500 Open in a separate window All anti-human antibodies were used for surface staining at 1/100 dilution, unless stated otherwise.

Techniques: Derivative Assay, Isolation, Flow Cytometry, Infection, Imaging, Cytometry, Selection

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: Injection of T3SS effectors not resulting in invasion is the main targeting mechanism of Shigella toward human lymphocytes

doi: 10.1073/pnas.1707098114

Figure Lengend Snippet: List of antibodies

Article Snippet: Antibodies used for purity and activation status are listed in . table ft1 table-wrap mode="anchored" t5 Table S1. caption a7 Antibody Source Method CD3-APC Beckman, IOTest IM2467 FC CD3-Biotin eBioscience, 13-0038-82 FC CD3-FITC eBioscience, 11-0037-42 FC CD3 Dako, A0452 IHC CD4-PerCPCy5.5 eBioscience, 45-0048-73 FC CD8a-PE eBioscience, 12-0088-73 FC CD19-APC eBioscience, 17-0199-73 FC CD19-Biotin eBioscience, 13-0199-82 FC CD19-PacificBlue BioLegend, 302232 FC CD19-PE eBioscience, 12-0199-42 FC CD20cy Dako, M0755 IHC CD25-PE BD Pharmingen, 555432 FC CD27-PECy7 eBioscience, 25-0279-42 FC CD44-APC BD Pharmingen, 559942 FC CD45-PE-Vio770 Miltenyi, 130-098-148 FC CD45-APC BioLegend, BLE304011 FC CD69-APC BD Pharmingen, 555533 FC CD86-PE eBioscience, 12-0869-73 FC Epcam-PE Miltenyi, 130-098-115 FC IgA-FITC Miltenyi, 130-093-071 FC IgD-PerCPCy5 BD Pharmingen, 561315 FC IgG-PE BD Pharmingen, 555787 FC IgM-APCCy7 BioLegend, 314520 FC Streptavidin-Qdot705 Invitrogen, Q10163MP FC; 2 μL Mouse Ig-AF568 Thermo Fisher, {"type":"entrez-nucleotide","attrs":{"text":"A11021","term_id":"489240","term_text":"A11021"}} A11021 IHC; 1/500 Rabbit Ig-AF647 Thermo Fisher, {"type":"entrez-nucleotide","attrs":{"text":"A21245","term_id":"641367","term_text":"A21245"}} A21245 IHC; 1/500 Open in a separate window All anti-human antibodies were used for surface staining at 1/100 dilution, unless stated otherwise.

Techniques:

Journal: Nature Communications

Article Title: CD103 + cDC1 and endogenous CD8 + T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function

doi: 10.1038/s41467-020-19833-3

Figure Lengend Snippet: a Experimental layout for ( b , c ). b , c Absolute number of MHC-II + CD11c + DCs (CD45 + Gr1 − CD19 − CD3e − pre-gates) in tumor ( b ) and spleen ( b ) of A20.GL tumor-bearing mice treated as outlined in ( a ). Each dot represents one mouse (Day 1, 2: n = 3/group; Day 3: n = 6/group; Day 7: n = 6–7/group). Data are plotted as mean ± SD. p -values were obtained from an unpaired two-tailed Student’s t test. d A20.GL tumor-bearing wild-type (WT) or Cd40 −/− mice received 3 × 10 6 CAR T cells intravenously (i.v.). The percentage of MHC-II hi CD11c int migratory DCs (migDC) in tumor-draining lymph-nodes (tdLNs) was analyzed on day 7. Data are plotted as mean ± SD and pooled from two independent experiments (WT: n = 6/group; Cd40 −/− : n = 4/group). p -values were determined by two-way ANOVA test. e A20.GL tumor-bearing mice received 3 × 10 6 CAR T cells i.v. and CCR7 surface expression was analyzed on day 7 on CD11b − CD103 − double-negative (DN) (orange), CD11b − CD103 + cDC1 (green), and CD11b + CD103 + cDC2 (blue) populations in the tumor. Gray histogram, flow minus one. f A20.GL tumor-bearing mice received 3 × 10 6 CAR T cells i.v. and the percentage of CD11b − CD103 − DN (orange), CD11b − CD103 + cDC1 (green), and CD11b + CD103 + cDC2 (blue) populations in the tumor was analyzed on day 7. g A20.GL tumor-bearing mice received 3 × 10 6 CAR T cells i.v. and the percentage of CD11b − CD8α − DN (orange), CD11b − CD8α + cDC1 (green), and CD11b + CD8α − cDC2 (blue) populations in the spleen was analyzed on day 7. h The cDC1/cDC2 ratio in A20.GL tumor-bearing WT mice is plotted in the tumor and spleen of mice treated in ( f , g ). i The cDC1/cDC2 ratio in A20.GL tumor-bearing Cd40 −/− mice is plotted on day 7 after receiving 3 × 10 6 CAR T cells. Data in ( e – i ) is plotted as mean ± SD and pooled from two independent experiments. Each dot represents one mouse ( e – h , n = 7/group; i , n = 4/group). p -values were obtained from an unpaired two-tailed Student’s t test. ns, non-significant; i.v. intravenous; resDC, resident DC. Source data are provided as a Source Data file.

Article Snippet: The following anti-mouse antibodies were used for flow cytometry: TruStain fcX (anti-mouse CD16/32) BioLegend Cat# 101319, RRID:AB_1574973, 5 μg/ml; anti-mouse CCR7 (clone 4B12) PE BioLegend, 120105, 2 μg/ml; anti-mouse CD3 (clone 17A2) BrilliantViolet510 BioLegend 100233, RRID:AB_2561387, 1 μg/ml; anti-mouse CD3ε (clone 145-2C11) PE-eFluor 610 eBioscience 61-0031, RRID:AB_2574514, 1 μg/ml; anti-mouse CD4 (GK1.5) AlexaFluor 700 eBioscience 56-0041, RRID:AB_493999, 0.1 μg/ml; anti-mouse CD8α (53-6.7) APC-eFluor 780 eBioscience 47-0081, RRID:AB_1272185, 0.1 μg/ml; anti-mouse/human CD11b (M1/70) AlexaFluor 700 eBioscience 56-0112, RRID:AB_657585), 0.1 μg/ml; anti-mouse CD11c (N418) APC-eFluor 780 eBioscience 47-0114, RRID:AB_1548663, 0.2 μg/ml; anti-mouse CD19 (eBio1D3) APC-eFluor 780 eBioscience 47-0193, RRID:AB_10853189, 0.1 μg/ml; anti-mouse CD19 (eBio1D3) PE eBioscience 12-0193, RRID:AB_657661, 0.1 μg/ml; anti-mouse CD19 (eBio1D3) PE-eFluor 610 eBioscience 61-0193, RRID:AB_2574536, 0.5 μg/ml; anti-mouse CD40 (1C10) PerCP-eFluor 710 eBioscience 46-0401, RRID:AB_2573677, 1 μg/ml; anti-mouse CD40L (MR1) PE eBioscience 12-1541, RRID:AB_465887, 0.2 μg/ml; anti-mouse CD45 (30-F11) BV605 BioLegend 103139, RRID:AB_2562341, 0.5 μg/ml; anti-mouse CD45 (30-F11) PE-Cy7 eBioscience 25-0451, RRID:AB_469625, 0.5 μg/ml; anti-mouse CD45.1 (A20) PE-eFluor610 eBioscience 61-0453, RRID:AB_2574560, 0.2 μg/ml; anti-mouse CD45.2 (104) PE-Cy7 eBioscience 25-0454, RRID:AB_2573350, 0.1 μg/ml; anti-mouse CD103 (2E7) BV711 BioLegend 121435, RRID:AB_2686970, 1 μg/ml; anti-mouse IFNγ (XMG1.2) PE-Cy7 eBioscience 25-7311, RRID:AB_1257211, 0.4 μg/ml; anti-moue IRF8 (V3GYWCH) PerCP-eFluor710 eBioscience 46-9852, 1.6 μg/ml; anti-mouse Ki-67 (SolA15) PE-eFluor610 eBioscience 61-5698, 0.1 μg/ml; anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5) PE-eFluor 610 eBioscience 61-5931, RRID:AB_2574639, 0.2 μg/ml; anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5) PE-Cy7 eBioscience 25-5931, RRID:AB_469662, 0.2 μg/ml; anti-mouse MHC class II (MHC-II) I-A/I-E (M5/114.15.2) BV510 BioLegend 107635, RRID:AB_2561397, 0.2 μg/ml; anti-human Myc-tag (9B11) AlexaFluor 647 Cell Signaling 2233 S, RRID:AB_10693328, 1:500.

Techniques: Two Tailed Test, Expressing

Journal: Nature Communications

Article Title: CD103 + cDC1 and endogenous CD8 + T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function

doi: 10.1038/s41467-020-19833-3

Figure Lengend Snippet: a Survival of naive BALB/c mice injected with 1 × 10 6 A20.GL cells intravenously (i.v.) and either left untreated or treated with 3 × 10 6 CD8 + m1928z-CD40L CAR T cells i.v. on day 7 (black arrow). For CD4 + T cell depletion, two cohorts of mice received 200 μg of anti-CD4 depletion antibody (GK1.5) by intraperitoneal (i.p.) injection 2x per week for 3–4 weeks (red arrows). One of two representative experiments is shown. b Experimental scheme for ( c , d ). c Tumor burden of mice injected with luciferase-expressing CD19 neg A20.CD19-KO cells was monitored using bioluminescence imaging. Average radiance per whole animal is plotted for the IgG treated mice ( n = 9) and the CD8 + T cell-depleted mice ( n = 10). d Survival of mice treated in ( b , c ). Naive age-matched BALB/c mice were used as controls. All p -values in figure were determined by a two-tailed log-rank (Mantel-Cox) test. ns, non-significant. Source data are provided as a Source Data file.

Article Snippet: The following anti-mouse antibodies were used for flow cytometry: TruStain fcX (anti-mouse CD16/32) BioLegend Cat# 101319, RRID:AB_1574973, 5 μg/ml; anti-mouse CCR7 (clone 4B12) PE BioLegend, 120105, 2 μg/ml; anti-mouse CD3 (clone 17A2) BrilliantViolet510 BioLegend 100233, RRID:AB_2561387, 1 μg/ml; anti-mouse CD3ε (clone 145-2C11) PE-eFluor 610 eBioscience 61-0031, RRID:AB_2574514, 1 μg/ml; anti-mouse CD4 (GK1.5) AlexaFluor 700 eBioscience 56-0041, RRID:AB_493999, 0.1 μg/ml; anti-mouse CD8α (53-6.7) APC-eFluor 780 eBioscience 47-0081, RRID:AB_1272185, 0.1 μg/ml; anti-mouse/human CD11b (M1/70) AlexaFluor 700 eBioscience 56-0112, RRID:AB_657585), 0.1 μg/ml; anti-mouse CD11c (N418) APC-eFluor 780 eBioscience 47-0114, RRID:AB_1548663, 0.2 μg/ml; anti-mouse CD19 (eBio1D3) APC-eFluor 780 eBioscience 47-0193, RRID:AB_10853189, 0.1 μg/ml; anti-mouse CD19 (eBio1D3) PE eBioscience 12-0193, RRID:AB_657661, 0.1 μg/ml; anti-mouse CD19 (eBio1D3) PE-eFluor 610 eBioscience 61-0193, RRID:AB_2574536, 0.5 μg/ml; anti-mouse CD40 (1C10) PerCP-eFluor 710 eBioscience 46-0401, RRID:AB_2573677, 1 μg/ml; anti-mouse CD40L (MR1) PE eBioscience 12-1541, RRID:AB_465887, 0.2 μg/ml; anti-mouse CD45 (30-F11) BV605 BioLegend 103139, RRID:AB_2562341, 0.5 μg/ml; anti-mouse CD45 (30-F11) PE-Cy7 eBioscience 25-0451, RRID:AB_469625, 0.5 μg/ml; anti-mouse CD45.1 (A20) PE-eFluor610 eBioscience 61-0453, RRID:AB_2574560, 0.2 μg/ml; anti-mouse CD45.2 (104) PE-Cy7 eBioscience 25-0454, RRID:AB_2573350, 0.1 μg/ml; anti-mouse CD103 (2E7) BV711 BioLegend 121435, RRID:AB_2686970, 1 μg/ml; anti-mouse IFNγ (XMG1.2) PE-Cy7 eBioscience 25-7311, RRID:AB_1257211, 0.4 μg/ml; anti-moue IRF8 (V3GYWCH) PerCP-eFluor710 eBioscience 46-9852, 1.6 μg/ml; anti-mouse Ki-67 (SolA15) PE-eFluor610 eBioscience 61-5698, 0.1 μg/ml; anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5) PE-eFluor 610 eBioscience 61-5931, RRID:AB_2574639, 0.2 μg/ml; anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5) PE-Cy7 eBioscience 25-5931, RRID:AB_469662, 0.2 μg/ml; anti-mouse MHC class II (MHC-II) I-A/I-E (M5/114.15.2) BV510 BioLegend 107635, RRID:AB_2561397, 0.2 μg/ml; anti-human Myc-tag (9B11) AlexaFluor 647 Cell Signaling 2233 S, RRID:AB_10693328, 1:500.

Techniques: Injection, Luciferase, Expressing, Imaging, Two Tailed Test

Journal: Oncotarget

Article Title: Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG’s receptor ILT2 on peripheral CD8 + T cells

doi: 10.18632/oncotarget.26036

Figure Lengend Snippet: Patient and tumor characteristics

Article Snippet: The following antibodies were used for cell surface staining and phenotyping: from Miltenyi Biotec: CD3-PerCP, CD4-VioBright-FITC, CD8-APC-Vio770, CD19-APC eBioscience: ILT2-PE (Clone HP-F1).

Techniques:

Journal: Oncotarget

Article Title: Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG’s receptor ILT2 on peripheral CD8 + T cells

doi: 10.18632/oncotarget.26036

Figure Lengend Snippet: ( A ) HLA-G expression in NMIBC biopsies. Two representative results obtained are shown. Brown labelling indicates HLA-G positivity. ( B ) Representative images of the results obtained for ILT2 cell-surface expression on CD8 + T cells from NMIBC patients with low (left) and high (right). Proportion of the ILT2-positive population within the CD8 + T cell population is indicated. ( C ) ILT2 expression levels on peripheral CD3 + CD4 + T cells and CD3 + CD8 + T cells for 25 healthy donors (HD), 20 aged-matched controls (Aged-matched), and 27 (for CD4 + T cells) or 76 (for CD8 + T cells) NMIBC patients. ( D ) Proportion of ILT2 + peripheral CD3 + CD4 + T cells and CD3 + CD8 + T cells at the time of inclusion from NMIBC patients who recurred and did not recur within 12 months. ( E ) Proportion of ILT2 + peripheral CD3 + CD8 + T cells at the time of inclusion from NMIBC patients who recurred and did not recur within 24 months. Mean and standard deviation are shown. P was calculated using Mann–Whitney test.

Article Snippet: The following antibodies were used for cell surface staining and phenotyping: from Miltenyi Biotec: CD3-PerCP, CD4-VioBright-FITC, CD8-APC-Vio770, CD19-APC eBioscience: ILT2-PE (Clone HP-F1).

Techniques: Expressing, Standard Deviation, MANN-WHITNEY

Journal: Oncotarget

Article Title: Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG’s receptor ILT2 on peripheral CD8 + T cells

doi: 10.18632/oncotarget.26036

Figure Lengend Snippet: ( A ) Analysis for the whole cohort. ( B ) Analysis for incident patients. ( C ) Analysis for prevalent patients. Recurrence-free survival curves are shown for Low (≤18% CD8 + ILT2 + T cells among CD8 + T cells) vs intermediate (19%–45% CD8 + ILT2 + T cells among CD8 + T cells) vs high (≥46% CD8 + ILT2 + T cells among CD8 + T cells).

Article Snippet: The following antibodies were used for cell surface staining and phenotyping: from Miltenyi Biotec: CD3-PerCP, CD4-VioBright-FITC, CD8-APC-Vio770, CD19-APC eBioscience: ILT2-PE (Clone HP-F1).

Techniques:

Journal: Oncotarget

Article Title: Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG’s receptor ILT2 on peripheral CD8 + T cells

doi: 10.18632/oncotarget.26036

Figure Lengend Snippet: Cox regression for factors associated with tumor recurrence

Article Snippet: The following antibodies were used for cell surface staining and phenotyping: from Miltenyi Biotec: CD3-PerCP, CD4-VioBright-FITC, CD8-APC-Vio770, CD19-APC eBioscience: ILT2-PE (Clone HP-F1).

Techniques: Isolation

Journal: Oncotarget

Article Title: Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG’s receptor ILT2 on peripheral CD8 + T cells

doi: 10.18632/oncotarget.26036

Figure Lengend Snippet: Calculation of the concordance index at different time points of the model with clinical variables alone, with CD8-ILT2 alone and with both clinical variables and CD8-ILT2

Article Snippet: The following antibodies were used for cell surface staining and phenotyping: from Miltenyi Biotec: CD3-PerCP, CD4-VioBright-FITC, CD8-APC-Vio770, CD19-APC eBioscience: ILT2-PE (Clone HP-F1).

Techniques: